論文

査読有り 国際誌
2022年3月27日

Efficacy and Safety of Acute Phase Intensive Electrical Muscle Stimulation in Frail Older Patients with Acute Heart Failure: Results from the ACTIVE-EMS Trial

Journal of Cardiovascular Development and Disease
  • Shinya Tanaka
  • Kentaro Kamiya
  • Yuya Matsue
  • Ryusuke Yonezawa
  • Hiroshi Saito
  • Nobuaki Hamazaki
  • Ryota Matsuzawa
  • Kohei Nozaki
  • Masashi Yamashita
  • Kazuki Wakaume
  • Yoshiko Endo
  • Emi Maekawa
  • Minako Yamaoka-Tojo
  • Takaaki Shiono
  • Takayuki Inomata
  • Junya Ako
  • 全て表示

9
4
開始ページ
99
終了ページ
99
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3390/jcdd9040099
出版者・発行元
MDPI AG

As frailty in older patients with acute heart failure (AHF) has an adverse effect on clinical outcomes, the addition of electrical muscle stimulation (EMS) to exercise-based early rehabilitation may improve the effects of treatment. Post hoc analysis was performed on a randomized controlled study for clinical outcomes and prespecified subgroups (ACTIVE-EMS: UMIN000019551). In this trial, 31 AHF patients aged ≥ 75 years with frailty (Short Physical Performance Battery [SPPB] score 4–9) were randomized 1:1 to receive treatment with an early rehabilitation program only (n = 16) or early rehabilitation with add-on EMS therapy (n = 15) for 2 weeks. Changes in physical function and cognitive function between baseline and after two weeks of treatment were assessed. There were no adverse events during the EMS period. The EMS group showed significantly greater changes in quadriceps’ isometric strength and SPPB compared to the control group, and EMS therapy showed uniform effects in the prespecified subgroups. There were no significant differences in the changes in other indexes of physical function and cognitive function between groups. There was no significant difference in the rate of heart failure hospitalization at 90 days between groups. In conclusion, older AHF patients with frailty showed greater improvement in lower extremity function with the addition of EMS therapy to early rehabilitation without adverse events.

リンク情報
DOI
https://doi.org/10.3390/jcdd9040099
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/35448075
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032621
URL
https://www.mdpi.com/2308-3425/9/4/99/pdf
ID情報
  • DOI : 10.3390/jcdd9040099
  • eISSN : 2308-3425
  • PubMed ID : 35448075
  • PubMed Central 記事ID : PMC9032621

エクスポート
BibTeX RIS